Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Her proof is in her posts. Let’s see if the next post has any merit.
Monkey Pox , people who have gotten are coming out and showing pictures and stating that you don’t want to get it. If their is an antiviral that can help, I think it would be huge IMO!
Exactly, the AE’s are associated with SOM not the treatment. Quite typical.
WHO declares Monkey Pox a world wide pandemic.
Provides excellent insight on OM potential. Let’s see if that leads to partnership $$$.
Yes, the rumor is PFE wanted him to help pull some strings at the FDA to give their Severe Hemophilia A drug in partnership with SGMO some favoritism over BMRN’s Rox HemA drug. Anything to delay, and close the time gap, etc. At least that is the rumor. And I will emphasize it’s hearsay with no basis in fact. But it makes you wonder.
Yep FDA employees are hoping for a high paying, do nothing job at Big Pharma as a pay off for all the favoritism.
Just pulling your leg. Obviously this is a gamble. Love the government lab independent research. Gives it some forward basis for opportunities.
I think you have to weigh what was tested on original CV and last years variants with recent findings not only in new CV variants, but other variants as well. BP had us covered last year for specific variants and that is being generous.
I think the results of recently completed testing and more ongoing testing is enlightening many.
That is just awesome research by the top, non-biased/ independent research labs in the world. Should get BP moving.
Have to admit this one has me worried. We can’t let BP only let their drugs get the nod. It’s nothing to mess around with, even BP needs to be concerned. So if their is an antiviral that has shown effective in lab testing….need to get moving now on it. Time is running out IMO.
The Marburg virus in Guinea maybe breaking containment. This is such a deadly virus that BP cannot mess around. Also Monkey virus is spreading fast. Need an antiviral that covers the gambit.
Yea B failed on patients that had no hope, organs failing. Horrible trial to get inventory with IMO
Good to here. The value of B is being proven by top government research labs. Be hard for Big Pharma to turn your head away from the possibilities and letting a competitor get B.
Looks like the stars are lining up to me!
Actually it’s never wrong in the very long term. In the short term , markets are driven by emotions: fear and greed.
Can hardly wait. The span of viruses being tested would most likely not have been done without government involvement and the scale involved. We are fortunate. Sounds like testing is completed now the publication is in progress. Still a gamble. Willing to add some at these levels.
Never thought I I’d say this, but I am planing on adding. Next set of news from Government Labs that will potentially differentiate B from all antivirals on how broad it’s application can span, could be mind blowing. Also expect other news, AS….etc.
By Rutgers U. Independent of Leo my friends. Looks like antiviral cure across the viral spectrum. I could see partners, or Government defense acquiring for National defense. IMO!
It’s is a good move.
Yes but the principal investigator said these weren’t associated with B, why ? Because they are typical for these patients and patients on Dap, even though in this one study the Dap arm had none of these AE’s.
Sounds like it.
AS is next. Predicting June trial start or news on trial with B. No insider knowledge.
For starters on the spikes: Advil, Motrin, Aleve, Naprosyn. Advil has also been known to actually burn holes in the colon…yet it’s still over- the- counter. You can figure out the rest. Not replying to another one of your posts as it turns into an endless tennis match. No time making too much $$$ elsewhere.
A lot of over-the-counter medicines have those AE’s not SAE’s mind you or worse.
We’ve been through the AE discussion before. Your claims are very misleading. As for efficacy, it was clearly superior.
Yes , B proved to be the superior drug. The FDA demands on the PHIII was just over the top and too expensive at a time new antibiotics fell out of favor. Maybe it will heat up again.
Sounds like a compelling case for government funding. Also AS news around the corner.
Yep, remember B is still the leading antiviral from Government lab work from the testing completed so far. Yeah it didn’t meet the PHII trial endpoints on saving peoples lives with failing organs, which even it’s anti inflammatory properties couldn’t over come. Not even sure you could call the PHII trial an antiviral trial. It was more of a last gasp , let’s try almost anything trial.
Did the computer model giving a drug to patients with failing organs? What it model it’s shown efficacy in. From ABSSSI to multiple trials the RBL’s have been performing . Can’t wait for the latest RBL testing results. AS on PHIII also.
Very possible. Maybe some nuggets. More looking for RBL news and AS. I mean what do you expect giving B to Patients where organs are failing. Maybe the next trial will be giving B to patients in Cardiac arrest.
Last minute holdouts for tax selling. Been brutal in many biotech’s . Good take is the selling is wrung out. Next year should be better.
So we need an Antiviral that works on many viruses. RBL news will mean partnership or BO. Estimate $2. AS May finally start trial.
PFE is incredibly talented at setting up a drug trial for success. They make sure the patients selected are top tier for success. Also when and how much to give a patient. They know the drugs limitations. Why they wanted patients within 3 days of symptoms. The results come out , they look like a cure, they get billions in orders…and so on. Maybe a lot of treatments would show effectiveness if taken within 3 days. I bet most lean towards one day IMO.
Still tax selling. News on RBL, deep dive analysis on PHII, or AS next.
PFE’s anti-viral given 3 days within onset of CV. They are really good at preselecting their trial participants. Wonder how B would have done after only 3 days. Have to see how well it does on variants. MRKs second set of data showed no difference from the control group. Panel thought the later patients may have had Delta. MRK patients are more randomized PFE is really good at their screening process, just like the vaccine. Wonder what is going on with the Government research?
Leo have a hint for longs. We are moving towards thinking strategically. You cannot think that way without a partner. That’s my take.
New PR, sounds like some bio markers in data moved positively. Doing more analysis, new trials planning based on results.
Wonder how the treatments would do against moderate to severe. I think we know. Still looking for some gems in the deeper analysis.